Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs

Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs

Bibliographic Details
Main Authors:	Michael J. Bond, Ling Chu, Dhanusha A. Nalawansha, Ke Li, Craig M. Crews
Format:	Article
Language:	English
Published:	American Chemical Society 2020-07-01
Series:	ACS Central Science
Online Access:	https://doi.org/10.1021/acscentsci.0c00411

Similar Items

A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo
by: Christiane Kofink, et al.
Published: (2022-10-01)

Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo
by: Guoshun Luo, et al.
Published: (2021-05-01)

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers
by: Sajid Khan, et al.
Published: (2022-03-01)

Targeted Protein Internalization and Degradation by ENDosome TArgeting Chimeras (ENDTACs)
by: Dhanusha A. Nalawansha, et al.
Published: (2019-05-01)

Mutant-selective degradation by BRAF-targeting PROTACs
by: Shanique Alabi, et al.
Published: (2021-02-01)

Retraction of “Targeted Protein Internalization and Degradation by ENDosome TArgeting Chimeras (ENDTACs)”
by: Dhanusha A. Nalawansha, et al.
Published: (2020-01-01)

VHL-recruiting PROTAC attenuates renal fibrosis and preserves renal function via simultaneous degradation of Smad3 and stabilization of HIF-2α
by: Jiayi Yang, et al.
Published: (2022-12-01)

Tubulin Resists Degradation by Cereblon-Recruiting PROTACs
by: Ivana Gasic, et al.
Published: (2020-04-01)

Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation
by: Chiara Maniaci, et al.
Published: (2017-10-01)

Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors
by: Lisa Goebel, et al.
Published: (2023-03-01)

Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs
by: Patrick Pfaff, et al.
Published: (2019-09-01)

Targeting Protein Kinases Degradation by PROTACs
by: Fei Yu, et al.
Published: (2021-06-01)

mRNA PROTACs: engineering PROTACs for high‐efficiency targeted protein degradation
by: Xiaoqi Xue, et al.
Published: (2024-02-01)

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
by: Fenglei Li, et al.
Published: (2022-11-01)

Synthesis and Biological Activity of a VHL-Based PROTAC Specific for p38α
by: Mónica Cubillos-Rojas, et al.
Published: (2023-01-01)

Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
by: Shaima’a Hamarsheh, et al.
Published: (2020-04-01)

Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy
by: Minghua Yuan, et al.
Published: (2021-07-01)

Overcoming Resistance to Drugs Targeting KRASG12C Mutation
by: Delong Jiao, et al.
Published: (2020-08-01)

Efficacy and Safety of KRASG12C Inhibitors in Advanced Solid Tumors with KRASG12C-mutated: A Single-arm Meta-analysis
by: TAN Dengxu, et al.
Published: (2023-07-01)

Targeted protein degradation in cancers: Orthodox PROTACs and beyond
by: Jin Li, et al.
Published: (2023-05-01)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
by: Sinan Ma, et al.
Published: (2022-07-01)

Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models
by: Daniel J. Sisler, et al.
Published: (2023-02-01)

From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation
by: Siqi Wang, et al.
Published: (2024-01-01)

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
by: Jeremy M. Kelm, et al.
Published: (2023-03-01)

Targeting androgen receptor degradation with PROTACs from bench to bedside
by: Xiaojuan Jia, et al.
Published: (2023-02-01)

Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs
by: Mikihiko Naito, et al.
Published: (2019-12-01)

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
by: Si-Min Qi, et al.
Published: (2021-05-01)

PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
by: Xin Han, et al.
Published: (2022-05-01)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
by: Arvind Negi, et al.
Published: (2022-11-01)

Selective degradation of the p53‐R175H oncogenic hotspot mutant by an RNA aptamer‐based PROTAC
by: Lingping Kong, et al.
Published: (2023-02-01)

The KRASG12C inhibitors in lung cancer therapy
by: Maciej Jędrak, et al.
Published: (2023-09-01)

Degradation of proteins by PROTACs and other strategies
by: Yang Wang, et al.
Published: (2020-02-01)

Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors
by: Abdel Mouti, M, et al.
Published: (2023)

The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
by: Firas Batrash, et al.
Published: (2023-11-01)

Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules
by: Behnam Nabet, et al.
Published: (2020-09-01)

Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)
by: Huifang Wang, et al.
Published: (2023-07-01)

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies
by: Nuwayo Ishimwe Sincere, et al.
Published: (2023-05-01)

Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis
by: Qi-An Chen, et al.
Published: (2024-02-01)

Adagrasib: A landmark in the KRASG12C‐mutated NSCLC
by: He Tian, et al.
Published: (2022-12-01)

PROTACs targeting epigenetic proteins
by: Chao Zhang, et al.
Published: (2023-12-01)